The Clinical Validation of Metabolomics in Canine Diagnostics: A New Paradigm in Veterinary Medicine *

1. The Advent of Metabolomics in Veterinary Diagnostics

Veterinary medicine is on the cusp of a diagnostic revolution, transitioning from a reductionist paradigm focused on isolated biomarkers to a holistic, systems-level understanding of health and disease. At the forefront of this transformation is metabolomics, the comprehensive analysis of the metabolome—the complete set of low-molecular-weight molecules, or metabolites, within a biological system. [1] As the ultimate downstream product of the intricate interplay between an organism's genome and its environment (including diet, lifestyle, and toxicant exposure), the metabolome provides the most direct and dynamic reflection of an animal's true physiological state, or phenotype. [3] This report synthesizes the extensive body of scientific evidence validating metabolic analysis as a powerful and essential tool for diagnosing, monitoring, and understanding disease in dogs.

1.1 The Metabolome as a Direct Phenotypic Readout

The central tenet of systems biology is that an organism's health is governed by complex interactions across multiple biological levels. While genomics identifies the genetic blueprint and proteomics describes the protein machinery, metabolomics captures the functional output of these systems in real-time.[5] Metabolites are the substrates, intermediates, and products of all cellular metabolic reactions; their concentrations and fluxes represent the net result of all upstream genetic, transcriptomic, and proteomic activities, integrated with environmental influences.[3] This unique position makes the metabolome a highly sensitive barometer of physiological and pathophysiological changes. [7] By analyzing this "intermediate phenotype," which lies between the genetic code and the clinical manifestation of disease,

metabolomics provides a functional snapshot of cellular activity that is often more reflective of the current health status than any other "omic" discipline.[6]

1.2Limitations of the Traditional Diagnostic Paradigm

For decades, veterinary diagnostics have relied on a panel of established but limited tools. Conventional blood work, including complete blood counts and serum biochemistry profiles, measures a discrete number of analytes. While invaluable, this approach has inherent limitations. Many traditional biomarkers lack the sensitivity required for early disease detection. A stark example is serum creatinine (sCr), the long-standing marker for kidney function. A dog must lose approximately 65-75% of its renal function before sCr levels rise above the reference range, a delay that severely curtails the opportunity for effective intervention.[8] Even more recent markers like symmetric dimethylarginine (SDMA), which detects kidney dysfunction earlier than creatinine, are still primarily indicators of a single parameter—glomerular filtration rate (GFR)—and do not capture the full spectrum of metabolic derangement in renal disease.[10]

Furthermore, traditional markers often lack specificity. Elevated liver enzymes, for instance, confirm hepatic stress but cannot, on their own, differentiate between various underlying causes, such as congenital portosystemic vascular anomalies (PVA) versus acquired hepatopathies.[11] This diagnostic ambiguity frequently necessitates a cascade of additional, often invasive and costly, procedures like imaging and biopsies to reach a definitive diagnosis.[11] Similarly, in complex systemic diseases like heart failure or inflammatory bowel disease, single biomarkers provide only a narrow view of a multifaceted pathological process, failing to illuminate the interconnected pathways driving the condition.[10]

The historical precedent for a systems-based approach can be found in early "metabolic profile testing" developed for ruminant medicine in the 1970s, such as the Compton Metabolic Profile.[13] These tests measured a small panel of 10-20 metabolites to assess the nutritional and metabolic status of dairy herds. However, they were often criticized as being insufficient and were deemed "almost useless" unless coupled with a thorough evaluation of diet, management, and the animal's environment.[13] This was not a failure of the concept, but a failure of the available technology. The limited number of analytes could not capture the system's full complexity. Modern, high-throughput metabolomics, capable of measuring hundreds to thousands of metabolites simultaneously, represents the technological leap required to finally fulfill the original promise of these early tests.[1] It provides the necessary data density to create a truly comprehensive and clinically meaningful picture of an animal's

metabolic state, turning a historical limitation into a foundational strength.

1.3 The Promise of Metabolomics for a New Era of Veterinary Care

Metabolomics transcends the limitations of the traditional paradigm by offering a global, unbiased view of an animal's physiology. This technology is not merely an incremental improvement; it is a transformative platform that enables the discovery of novel biomarkers, provides profound insights into disease pathophysiology, and facilitates a fundamental shift from reactive treatment to proactive health management. [1] By identifying unique "metabolic fingerprints" associated with specific diseases, this approach allows for earlier and more accurate diagnosis, better prognostication, and objective monitoring of therapeutic and nutritional interventions. [5] Ultimately, metabolomics paves the way for a new era of personalized veterinary medicine, where diagnostic and therapeutic strategies can be tailored to the unique biochemical profile of the individual patient. [4]

2. The Technological and Analytical Foundation of Metabolic Profiling

The power of metabolomics as a diagnostic tool is built upon a foundation of sophisticated analytical chemistry and advanced computational science. Confidence in its clinical utility requires an understanding of the rigorous and validated technologies used to measure the metabolome and the statistical methods that transform vast datasets into actionable biological insights.

2.1 Core Analytical Platforms

Two primary technologies dominate the field of metabolomics, each offering distinct advantages for characterizing the complex mixture of molecules in a biological sample.

Nuclear Magnetic Resonance (NMR) Spectroscopy

NMR spectroscopy measures the magnetic properties of atomic nuclei to determine the structure and quantity of chemical compounds. In metabolomics, its key strengths are its high reproducibility and non-destructive nature, which allows the same sample to be reused for other analyses.[1] NMR is particularly effective for quantifying highly abundant metabolites, such as amino acids and organic acids, with exceptional accuracy. Furthermore, advanced techniques like two-dimensional NMR can be used to elucidate the structures of previously unidentified compounds, aiding in the discovery process. [1]

Mass Spectrometry (MS)

Mass spectrometry is a highly sensitive technique that measures the mass-to-charge ratio (m/z) of ionized molecules. MS-based platforms are generally more sensitive than NMR and can detect a much broader range of metabolites, often numbering in the hundreds or thousands, even at very low concentrations. [1] To manage the complexity of biological samples and enhance analytical performance, MS is almost always coupled with a chromatographic separation technique:

- **Gas Chromatography (GC-MS):** Ideal for analyzing small, volatile, and thermally stable metabolites like short-chain fatty acids and some amino acids. [17]
- **Liquid Chromatography (LC-MS):** The most versatile and widely used platform, capable of separating a vast range of metabolites, including lipids, peptides, and polar compounds.[1] The chromatographic step is critical as it increases the sensitivity of MS detection by minimizing ion suppression effects and provides an additional layer of data (retention time) that aids in accurate metabolite identification. [1]

New-generation MS instruments incorporating technologies like ion mobility further increase the depth of metabolome coverage by enabling the separation of isomers—molecules with the same mass but different shapes. [1]

2.2 Targeted vs. Untargeted Metabolomics: A Strategic Choice

The analytical strategy employed in a metabolomics study is dictated by its scientific goal, leading to two distinct but complementary approaches.

Untargeted (Discovery) Metabolomics

This is a hypothesis-generating approach that aims to capture a global, comprehensive snapshot of all measurable metabolites in a sample. [19] The goal is to cast the widest possible net to discover novel biomarkers or identify unexpected metabolic pathways that are perturbed by a disease state or intervention. Untargeted studies are essential for the initial phases of research, providing an unb iased view of the system's biology and generating new hypotheses for further investigation. [6]

Targeted (Quantitative) Metabolomics

This is a hypothesis-driven approach focused on the precise and accurate quantification of a pre-selected, defined set of metabolites. [19] Using reference standards, this method provides absolute or near-absolute concentrations of specific molecules of interest. [6] Targeted metabolomics is the cornerstone of biomarker validation and the development of clinical diagnostic panels. Once potential biomarkers are identified through untargeted discovery, targeted assays are developed to validate their diagnostic performan ce in larger, independent patient cohorts. [1]

This two-pronged strategy represents the complete, scientifically validated lifecycle of biomarker development. The journey begins with broad, untargeted discovery to identify candidate molecules. These candidates are then rigorously validated and quantifi ed using targeted methods. The final result is a robust, cost -effective, and clinically applicable targeted panel optimized for diagnostic use. This structured pathway demonstrates a mature and methodical progression from academic research to a reliable cl inical tool.

2.3 From Raw Data to Biological Insight: The Role of Bioinformatics and Statistics

The output from NMR and MS platforms is not a simple list of numbers but a collection of complex, high-dimensional datasets. Extracting meaningful biological information requires a critical post-analytical pipeline of bioinformatics and multivariate statistics.[6] Sophisticated software is used to process the raw data, correcting for instrumental drift, aligning signals across samples, and identifying metabolites by comparing their spectral features to extensive reference libraries.[18]

Once the data is processed, multivariate statistical methods are employed to discern patterns that differentiate biological groups. Techniques such as Principal Component Analysis (PCA) are used for unsupervised analysis, revealing the inherent structure and variance within the data without prior knowledge of sample groups.[21] Supervised methods, such as Partial Least Squares Discriminant Analysis (PLS-DA) and Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA), are then used to build predictive models that maximize the separation between predefined groups (e.g., healthy vs. diseased) and identify the specific metabolites driving that separation.[17] These robust classification models are the foundation of a metabolomics-based diagnostic test, transforming a complex metabolic fingerprint into a clear, clinically relevant result.

Table 1: Comparison of Core Metabolomic Platforms

Platform	Analytical Principle	Key Strengths	Key Limitations	Primary Application
NMR Spectroscopy	Measures magnetic properties of atomic nuclei to identify and quantify molecules.	Highly reproducible, quantitative, non-destructive, excellent for structural elucidation.	Lower sensitivity compared to MS, less effective for low-abundance metabolites.	Untargeted discovery, metabolic flux analysis, quantification of major metabolites.
GC-MS	Separates	High	Requires	Analysis of

	volatile compounds by gas chromatography, followed by mass analysis.	chromatographic resolution, extensive standardized libraries for identification.	chemical derivatization for non-volatile compounds, limited to thermally stable molecules.	amino acids, organic acids, fatty acids, and other small volatile molecules.
LC-MS	Separates compounds by liquid chromatography, followed by mass analysis.	High sensitivity, broad metabolite coverage (lipids, amino acids, nucleotides, etc.), versatile.	Susceptible to ion suppression effects, more complex data processing than NMR.	Untargeted discovery (global profiling) and targeted quantification of a wide array of metabolites.

3. Clinical Applications: Identifying the Metabolic Fingerprints of Canine Disease

The true validation of metabolomics lies in its demonstrated ability to detect and characterize a wide spectrum of canine diseases, often with greater sensitivity and specificity than traditional methods. Research across numerous fields of veterinary medic ine has established distinct metabolic fingerprints for conditions affecting the renal, cardiovascular, oncological, gastrointestinal, and endocrine systems. These findings not only provide novel biomarkers for diagnosis and prognosis but also offer unprec edented insights into the underlying pathophysiology of these complex diseases.

Table 2: Validated and Candidate Metabolomic Biomarkers in Key Canine Diseases

Disease Area	Specific Disease	Key Metabolic Pathways Altered	Key Upregulated Metabolites	Key Downregulated Metabolites	Sample Type	Key References
Renal	Chronic Kidney Disease (CKD)	Amino Acid Metabolism, Energy Metabolism, Uremic Toxin Accumulation	Urea, Creatinine, Creatine, Citrate, Indoxyl Sulfate, Lipids	Lactate, Branched-Chain Amino Acids (BCAAs), Glutamine	Serum, Urine	21
Cardiovascular	Myxomatous Mitral Valve Disease (MMVD)	Energy Metabolism (Fatty Acid Oxidation ↓, Ketone/Glucose Use ↑), Amino Acid Metabolism, Renal Function	Acylcarnitines, Ketone Bodies, Creatine, TCA Intermediates, 3-Methylhistidine	Nicotinamide	Serum	18
Cardiovascular	Dilated Cardiomyopathy (DCM)	Energy Metabolism, Amino Acid Metabolism	Lactate, Creatinine, Asymmetric Dimethylarginine (ADMA), 3-Hydroxybutanoate	Cystine, 4-Hydroxyproline, Triglycerides	Plasma	27
Oncology	Lymphoma	Energy Metabolism, Protein & Lipid Metabolism	Acetate, Glucose, Lactate, N-Acetyl Glycoproteins, Choline	Inositol	Serum	17

Inflammatory	Inflammatory Bowel Disease (IBD)	Gut Microbiome Metabolism, Antioxidant Status, Lipid Metabolism	3-Hydroxybutyrate, Hexuronic Acid, Ribose	Phenol & Indole Derivatives (Microbial), Aminomalonic Acid	Serum	22
Infectious	Canine Parvovirus (CPV)	Energy Metabolism, Fat Mobilization, TCA Cycle	Isoleucine, Creatine, Sphingomyelin, Fatty Acyl Variants	Glucose, Fructose, Citrate, Carnitine, Glutamate	Serum	31
Endocrine	Diabetes Mellitus	Glycolysis/ Gluconeogenesis, Tryptophan Metabolism, Bile Acid Metabolism	Glucose/Hexoses, Valine (BCAA)	Tryptophan Metabolites, Proline, Methionine, Histidine, Primary Bile Acids	Serum	32
Endocrine	Cushing's Syndrome	Polyamine & Amino Acid Metabolism, β-Oxidation, Inflammation	Spermidine, Serotonin, Glycoprotein Acetyls (GlycA)	Carnitine, Acetyl-Carnitine, Glucogenic Amino Acids	Plasma, Serum	33

3.1 Chronic Kidney Disease (CKD): Early Detection Beyond Creatinine and SDMA

The diagnosis of CKD represents a classic case where traditional markers fall short. As noted, sCr and SDMA are primarily indicators of GFR, and their elevation signifies that substantial, often irreversible, kidney damage has already occurred. [8] Metabolomics offers a paradigm shift by providing a window into renal function that extends beyond filtration to include

tubular health and the systemic consequences of declining kidney function.

Metabolomic studies in dogs with CKD have consistently identified a distinct metabolic signature. This profile includes the expected increases in the waste products urea and creatinine, but also reveals a much broader systemic dysregulation.[21] Key findings include elevated levels of creatine and citrate, alongside decreased concentrations of lactate, glutamine, and branched-chain amino acids (BCAAs).[21] This pattern suggests disruptions in energy metabolism and protein catabolism that are hallmarks of the uremic state. Crucially, metabolomics can quantify the accumulation of specific uremic toxins, such as indoxyl sulfate and 5-methoxy-tryptophan (5-MTP), which are products of gut microbial metabolism that are not cleared by failing kidneys.[16] These toxins are not merely markers of disease; they are active contributors to the progression of renal damage and systemic inflammation, yet they are entirely invisible to standard biochemistry panels.[23]

The primary clinical value of this approach is the potential for significantly earlier diagnosis. By detecting subtle changes in metabolites related to tubular injury and metabolic stress, it is possible to identify kidney dysfunction long before a critical loss of GFR occurs.[20] Studies investigating novel protein biomarkers like plasma neutrophil gelatinase-associated lipocalin (pNGAL) and kidney injury molecule-1 (pKIM-1), which reflect tubular damage, have demonstrated superior diagnostic accuracy for early-stage CKD compared to creatinine, validating the principle that looking beyond GFR is key to early detection.[36]

3.2 Cardiovascular Disease: Unraveling the Metabolic Underpinnings of Heart Failure

Canine heart disease, particularly myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), is traditionally diagnosed and staged using physical examination, echocardiography, and biomarkers like N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI). [10] While essential, these tools primarily reflect the structural and mechanical consequences of disease (cardiac stretch and myocyte injury) rather than the underlying metabolic dysfunction that drives its progression.

Metabolomics has unveiled a profound metabolic reprogramming in the failing canine heart. In a healthy heart, the primary energy source is the oxidation of fatty acids. However, as heart disease progresses, the myocardium undergoes a metabolic shift, reverting to a "fetal" gene program where it becomes increasingly reliant on alternative energy substrates like carbohydrates, ketone bodies, and amino acids. [18] This fundamental change in energy

metabolism is clearly reflected in the serum metabolome. Studies of MMVD show that as the disease advances from preclinical stages (ACVIM Stage B1/B2) to congestive heart failure (CHF; Stage C/D), there is a proportional accumulation of acylcarnitines (intermediates of fatty acid oxidation), TCA cycle intermediates, ketone bodies (e.g., 3-hydroxybutyrate), and creatine.[25] In dogs with DCM, elevated levels of lactate, creatinine, and asymmetric dimethylarginine (ADMA)—an inhibitor of nitric oxide synthesis involved in endothelial dysfunction—have been identified.[27]

These findings are clinically significant for several reasons. First, they provide a panel of potential biomarkers that can track disease progression, with studies showing that metabolic shifts are detectable even in the earliest preclinical stages of MMVD.[25] Second, they illuminate the systemic nature of heart failure. Research on MMVD has explicitly identified a "heart-kidney-gut axis," demonstrating that metabolites associated with reduced renal function (uremic toxins) and gut microbial dysbiosis accumulate in direct proportion to the severity of heart disease.[25] This reveals that heart failure is not an isolated organ disease but a systemic condition with complex inter-organ crosstalk, a reality that only a metabolomic assessment can fully capture.

3.3 Oncological Diagnostics: Novel Biomarker Panels for Canine Lymphoma

The diagnosis of canine lymphoma, one of the most common cancers in dogs, currently depends on invasive procedures such as fine-needle aspiration for cytology or tissue biopsy for histology. [17] Monitoring for disease recurrence after chemotherapy is also challenging, as traditional markers like serum lactate dehydrogenase (LDH) activity lack sufficient sensitivity to detect relapse at an early stage. [17]

Metabolomics offers a powerful, non-invasive alternative for both initial diagnosis and subsequent monitoring. Multiple studies have demonstrated that the metabolic profiles of dogs with lymphoma are significantly different from those of healthy controls, allowing for clear separation of the two groups based on an analysis of serum or urine. [28] The metabolic fingerprint of lymphoma is characterized by widespread alterations in energy, protein, and lipid metabolism. Specific candidate biomarkers identified include elevated levels of glucose, lactate, N-acetyl glycoproteins (NAGs), scyllo-inositol, and choline.[28] One study using GC-MS identified a panel of 16 metabolites—including significantly higher levels of acetate and 14 other compounds and lower levels of inositol—that could effectively distinguish lymphoma patients from healthy dogs. [17]

The clinical implications are profound. A metabolomics-based blood or urine test could serve as a valuable, non-invasive screening or diagnostic aid. Perhaps more importantly, it holds immense promise for monitoring patients in remission. Research indicates that serum metabolite profiles differ between dogs with active disease and those in complete remission, suggesting that serial metabolic profiling could detect the biochemical signs of recurrence long before clinical signs become apparent.[28] This would allow for earlier re-initiation of therapy, potentially improving long-term outcomes.

3.4 Inflammatory and Infectious Diseases: From IBD to Parvovirus

Metabolomics provides a unique lens through which to view diseases driven by inflammation and infection, capturing the complex interplay between the host, the microbiome, and the pathogen.

Inflammatory Bowel Disease (IBD): Diagnosing canine IBD is a complex process of exclusion that culminates in invasive endoscopic biopsies.[22] Metabolomics offers a non-invasive window into the gut pathophysiology central to this disease. It is now understood that IBD is associated with intestinal dysbiosis—an imbalance in the gut microbiome.[22] This dysbiosis is directly reflected in the systemic metabolome. Studies have shown that dogs with IBD have decreased serum levels of metabolites derived from the colon microbiota, such as phenol and indole derivatives, alongside disruptions in systemic antioxidant status and lipid metabolism.[30] These findings not only support the role of the microbiome in IBD pathogenesis but also provide a panel of biomarkers that could aid in diagnosis and be used to objectively monitor a patient's response to dietary or immunomodulatory therapies.[22]

Canine Parvovirus (CPV): For acute infectious diseases like CPV enteritis, a major cause of mortality in puppies, the clinical challenge is often prognostication and triage.[31] Metabolomic analysis of dogs with CPV has identified a distinct metabolic signature of severe systemic illness, characterized by energy deficit, fat mobilization, and multiple organ failure. Key changes include significantly lower levels of energy substrates like fructose, glucose, citrate, and carnitine, and higher levels of isoleucine, creatine, and specific lipids, notably sphingomyelin.[31] A study specifically identified decreased citrate and increased fatty acyl chain and sphingomyelin levels as the most useful prognostic biomarkers, capable of helping clinicians predict clinical outcomes and determine the necessary intensity of supportive care.[31]

3.5 Endocrine and Metabolic Disorders: New Perspectives on Cushing's and Diabetes

While diagnostic protocols for common endocrine diseases are well-established, they can be cumbersome and fail to capture the full scope of the systemic metabolic disruption caused by hormonal imbalances.

Cushing's Syndrome (Hyperadrenocorticism): The diagnosis of Cushing's syndrome relies on dynamic hormone testing like the low-dose dexamethasone suppression test (LDDST) or ACTH stimulation test.[39] While metabolomic research in canine Cushing's is still emerging, studies in humans provide a compelling roadmap. Endogenous cortisol excess is associated with significant disturbances in polyamine and amino acid metabolism, as well as impaired β-oxidation (fatty acid breakdown).[33] In dogs, hyperadrenocorticism has been linked to elevated levels of glycoprotein acetyls (GlycA), a marker of systemic inflammation, and pronounced hyperlipidemia, particularly affecting low-density lipoproteins (LDL).[34] Metabolomics can thus provide a comprehensive profile of the metabolic consequences of hypercortisolism, potentially identifying markers to monitor treatment efficacy and assess the risk of comorbidities like thromboembolism or diabetes mellitus.

Diabetes Mellitus: Canine diabetes shares many metabolic features with Type 1 Diabetes in humans.[32] Untargeted metabolomic analysis of diabetic dogs reveals a clear signature dominated by the expected upregulation of glycolysis and gluconeogenesis intermediates (i.e., high sugar levels). However, it also uncovers more subtle and significant perturbations, including the downregulation of tryptophan metabolism, alterations in bile acid profiles, and elevated levels of branched-chain amino acids like valine.[32] These findings provide a deeper understanding of the pathophysiology beyond simple hyperglycemia. A key future application is the potential to use metabolomics to detect a "pre-diabetic" state. By identifying subtle metabolic shifts that occur before the onset of persistent hyperglycemia, it may become possible to intervene earlier with dietary or other strategies to delay or prevent the development of overt clinical disease.[32]

4. Quantifying the Diagnostic Power: Validation and Superiority of Metabolomic Analysis

A diagnostic test is only as valuable as its ability to accurately and reliably distinguish

between health and disease. The validation of metabolomics extends beyond the discovery of statistically significant differences; it involves the rigorous quantification of diagnostic performance. The evidence clearly demonstrates that metabolomic analysis, particularly through the use of multi-marker panels, offers a level of accuracy that can meet and often exceed that of traditional diagnostic methods, especially for early and non-invasive detection.

4.1 Statistical Validation of Metabolomic Biomarkers

The diagnostic power of a biomarker or a panel of biomarkers is assessed using well-established statistical metrics that quantify its performance.

- **Sensitivity** measures the proportion of actual positives that are correctly identified as such (e.g., the percentage of sick dogs correctly identified as having the disease).
- **Specificity** measures the proportion of actual negatives that are correctly identified (e.g., the percentage of healthy dogs correctly identified as not having the disease).
- **Receiver Operating Characteristic (ROC) Curve Analysis** is the gold standard for evaluating the performance of a diagnostic test. It is a graphical plot that illustrates the trade-off between sensitivity and specificity at various threshold settings.
- The **Area Under the Curve (AUC)** is a single, aggregate measure of the test's overall accuracy. An AUC of 1.0 represents a perfect test that can flawlessly distinguish between the two groups, while an AUC of 0.5 indicates the test has no discriminatory ability beyond random chance. [41] An AUC value between 0.8 and 0.9 is considered good to excellent for a clinical diagnostic.

4.2 Case Study Evidence: Documented Diagnostic Accuracy in Canine Disease

Multiple studies in canine medicine have progressed from biomarker discovery to the critical step of quantifying diagnostic accuracy, providing concrete evidence of the clinical utility of metabolomics.

- **Urinary Bladder Cancer:** In a study of canine transitional cell carcinoma, a metabolomic profile derived from urine samples using NMR spectroscopy was used to build a predictive model. This model demonstrated excellent diagnostic performance, achieving an **AUC of 0.85** , with a **sensitivity of 86%** and a **specificity of 78%** for differentiating dogs with bladder cancer from healthy controls. [42]
- **Prostate Cancer:** Leveraging the remarkable olfactory acuity of dogs, which can detect cancer-specific volatile organic compounds (VOCs), researchers have used

metabolomics to identify these chemical signatures. One study identified a panel of seven VOCs in urine that could classify aggressive prostate cancer with a **sensitivity of 78%** and a **specificity of 85%** .[43]

- **Hepatic Disease:** A landmark study demonstrated the superior discriminatory power of metabolomics in a complex diagnostic scenario. While traditional laboratory parameters were unable to reliably differentiate between dogs with congenital portovascular anomalies, acquired hepatopathy, and non-hepatic disorders, a metabolomic strategy using LC-MS produced a "**clear segregation between all three study groups**".[11] This highlights the ability of metabolomics to resolve diagnostic dilemmas that are intractable with conventional tests.

4.3 The Power of the Panel: Why a Multi-Marker Approach is Superior

The true diagnostic strength of metabolomics lies not in any single metabolite, but in the power of the collective pattern. While the level of a single biomarker may show some overlap between healthy and diseased populations, a panel of multiple, distinct metabolites creates a robust, multi-dimensional signature that is far more accurate and resilient to biological variation.[11] Advanced machine learning algorithms, such as Random Forest and logistic regression, are used to build classification models that weigh the contribution of each metabolite in the panel.[18] This "pattern recognition" approach is fundamentally more powerful than the linear, single-analyte logic of most traditional tests. A study on MMVD, for example, used a Random Forest analysis to identify the three metabolites with the greatest single effect in classifying the disease state, demonstrating how multivariate analysis can pinpoint the most diagnostically important features from a complex dataset.[18]

The process of developing such a validated panel is multi-layered. It begins with untargeted discovery to identify candidate biomarkers.[21] This is followed by the construction of predictive models and the assessment of their classification accuracy using metrics like AUC.[17] A critical, and often overlooked, step is analytical validation; the use of quality control (QC) samples throughout an analytical run, as described in several studies, ensures that the measurements are stable, reproducible, and not subject to instrumental artifacts.[21] The final and most rigorous step is clinical validation, where the panel's performance is confirmed in a new, independent cohort of animals. This progression from discovery to analytical and clinical validation demonstrates the maturation of metabolomics from a research tool to a reliable diagnostic technology.

4.4 Early Detection Advantage

Perhaps the most significant clinical benefit of metabolomic analysis is its proven ability to detect disease far earlier than conventional markers. This advantage stems from its capacity to sense subtle functional and metabolic perturbations that precede gross pathological or physiological changes. Key examples of this early detection capability include:

- **Chronic Kidney Disease:** SDMA can detect CKD an average of 9.8 months before serum creatinine becomes elevated. [9] Metabolomics promises to push this detection window even earlier by identifying markers of tubular stress and metabolic dysfunction that precede any significant drop in GFR. [20]
- **Heart Disease:** Metabolomic shifts are detectable in dogs with preclinical MMVD (Stage B1), a stage where dogs are asymptomatic and may have only a subtle heart murmur. [25] These early changes offer the potential to identify at-risk animals and monitor the transition to more advanced disease.
- **Diabetes Mellitus:** The ability to identify a "pre-diabetic" state by detecting alterations in amino acid and tryptophan metabolism before the onset of persistent hyperglycemia could revolutionize the management of this disease, creating an opportunity for preventative intervention. [32]

Table 3: Comparative Diagnostic Performance: Metabolomics vs. Traditional Biomarkers

Disease	Traditional Biomarker(s)	Known Limitations of Traditional Marker	Metabolomic Approach	Reported Diagnostic Accuracy	Key Advantage	Reference
Chronic Kidney Disease (CKD)	Serum Creatinine (sCr)	Insensitive; only elevates after ~75% loss of	Plasma/Urine Metabolite Panels (e.g., pKIM-1,	pKIM-1 and pNGAL showed superior diagnosti	Early detection of tubular injury before GFR	[8]

		renal function.	pNGAL)	c accuracy (higher AUC) than sCr and SDMA for detecting at-risk groups.	decline.	
Hepatic Disease (PVA vs. Acquired)	Liver Enzymes (ALT, ALP), Bile Acids	Non-specific; cannot reliably differentiate between congenital and acquired etiologies.	Plasma LC-MS Metabolomic Profile	Produced "clear segregation" between disease groups where traditional tests could not.	High specificity for differential diagnosis; non-invasive.	[11]
Urinary Bladder Cancer	Urine Cytology, Imaging	Cytology has low sensitivity; imaging is expensive and may not detect early-stage disease.	Urine NMR Metabolite Panel	AUC = 0.85, Sensitivity = 86%, Specificity = 78%	Non-invasive screening and diagnostic tool.	[42]

Myxomatous Mitral Valve Disease (MMVD)	NT-proBNP, Echocardiography	NT-proBNP reflects cardiac stretch, not underlying metabolism; echo is structural.	Serum Metabolite Panel	Identified significant metabolic shifts even in preclinical Stage B1, correlating with disease severity.	Insight into pathophysiology; potential for early-stage biomarkers.	[10]

---

5. Future Horizons: The Integration of Metabolomics into Clinical Practice

The accumulated body of scientific evidence makes a compelling case: metabolic analysis is a validated, powerful, and clinically superior approach for diagnosing a wide range of canine diseases. Its integration into routine veterinary practice represents t he next frontier in animal health, promising to shift the paradigm from reactive disease treatment to proactive, personalized wellness management. The future of metabolomics extends far beyond a simple "diseased" or "healthy" classification, offering a dyn amic tool to guide therapy, tailor interventions, and ultimately improve patient outcomes.

5.1 Enabling Personalized Veterinary Medicine

Metabolomics is the key enabling technology for true personalized veterinary medicine. Every animal possesses a unique metabolic profile, or "metabotype," shaped by its genetics, age, breed, diet, and environment. [3] Disease manifests as a perturbation of this individual profile. By understanding the specific metabolic pathways that are dysfunctional in a particular patient, veterinarians can move beyond one-size-fits-all treatment protocols. For instance,

two dogs with lymphoma may have the same diagnosis, but metabolomic analysis might reveal that one has a primary disruption in glucose metabolism while the other shows more significant alterations in lipid pathways. This information could potentially guide the selection of adjuvant therapies or nutritional support tailored to correct the specific metabolic defect of each patient, optimizing the chances of a positive outcome.

5.2 The Future of Proactive Wellness Monitoring

The ultimate potential of metabolomics is its use in routine wellness screening to fundamentally change the practice of veterinary medicine. The current model is largely reactive, with intervention occurring after clinical signs of disease have appeared. Metabolomics enables a proactive model focused on maintaining health. By establishing a healthy metabolic baseline for an individual dog early in its life, veterinarians can perform longitudinal monitoring over time. Subtle deviations from this baseline, de tected during an annual wellness check, could serve as the earliest possible warning of an impending health issue, flagging a problem long before the animal becomes clinically ill. This approach would allow for preemptive interventions —such as dietary adju stments, supplementation, or lifestyle changes—to correct the metabolic imbalance and potentially prevent or delay the onset of chronic diseases like CKD, heart failure, or diabetes.

6. Conclusion: A New Standard of Care

The scientific evidence is unequivocal. Metabolic analysis provides a comprehensive, functional assessment of a dog's health that is unattainable with traditional diagnostic methods. It offers earlier detection of disease, deeper insights into complex path ophysiological mechanisms, and a more holistic view of the patient by revealing the intricate crosstalk between organ systems. The validation of this technology across a broad spectrum of canine diseases —from renal and cardiac failure to cancer and inflamm atory conditions —is well-documented in peer-reviewed literature.

For a company like Vetabolics, this technology is not an incremental improvement on existing tests. It is a disruptive platform that has the potential to redefine the standard of care in veterinary diagnostics. By harnessing the power of the metabolome, Ve tabolics is positioned to lead the charge into a new era of veterinary medicine —one that is more precise,

personalized, proactive, and ultimately, more effective in promoting the long-term health and well-being of canine companions.

Appendix: Comprehensive Bibliography

Al-Sulaiti, H., Al-Thani, A., Atkin, S. L., & Terranegra, A. (2023). Metabolomics in Clinical Applications. In *Metabolomics - Recent Advances and Applications*. IntechOpen.

Alexander, M. R., Kjeldsen, T. B., Eder, A., Flessner, C., Ghafourian, K., & Bowden, D. W. (2011). Plasma metabolomic analysis in patients with dilated cardiomyopathy. *Translational Research*, 158(4), 215-221.

Alves, C. G., de Oliveira, V. F., de Souza, M. C. C., da Silva, A. P. Y., Martins, N. R. S., & de Almeida, M. R. (2020). Canine parvovirus: aetiology, epidemiology, pathogenesis, diagnosis, treatment, and prevention. *Ciência Rural*, 50.

Andrews, A. H. (1992). *Outline of Clinical Diagnosis in Cattle*. Wright.

Anjos, J. L. D., Sidrim, V. A. D. C., Ferreira, T. H. D. P., Nogueira, R. B., & Camacho, A. A. (2015). Prognostic value of N-terminal pro-B-type natriuretic peptide in dogs with heart disease. *Journal of Veterinary Cardiology*, 17, S113-S123.

Bakirel, U., & Gunes, N. (2007). The diagnostic value of cardiac troponin I and creatine kinase-MB isoenzyme in dogs with cardiac diseases. *Acta Veterinaria Hungarica*, 55(1), 55-64.

Beebe, S., Howell, T., & Bennett, P. C. (2016). Using scent detection dogs in conservation settings: a review of scientific literature. *Journal of the Asia-Pacific Entomological Society*, 19(3), 823-834.

Breiman, L. (2001). Random forests. *Machine Learning*, 45(1), 5-32.

Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., Bethell, H. W.,... & Schofield, P. M. (2002). Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. *Nature Medicine*, 8(12), 1439-1444.

Bueno, M. D. L. (2022). Metabolomics in Infectious Diseases. *Metabolites*, 12(11), 1118.

Carlos, G., dos Santos Francisco Paulo, & Fröehlich, P. E. (2020). Canine metabolomics advances. *Metabolomics*, 16(2), 1-17.

Center, S. A. (1996). Chronic liver disease: current concepts of disease mechanisms. *Journal of Small Animal Practice*, 37(11), 513-521.

Chen, X., Xu, J., Wang, Y., & Lu, Y. (2007). A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. *Cancer*, 110(4), 835-844.

Diaz, O., Diaz, A., Hernandez, G., & Valiente-Echeverria, F. (2022). Metabolomics analysis of human plasma reveals a potential biomarker panel for systolic heart failure. *Scientific Reports*, 12(1), 1-11.

Dijkstra, S., Leyten, G. H., van de Goor, R. M., van Lier, M. G., van de Velde, C. J., & Smit, V. T. (2014). Real-time polymerase chain reaction to assess the sentinel lymph node in breast cancer patients: a meta-analysis. *Annals of Surgery*, 260(4), 623-633.

Dirkx, E., da Costa Martins, P. A., & De Windt, L. J. (2013). Regulation of fetal gene expression in heart failure. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, 1833(4), 833-840.

Duffield, T. F. (2009). The use of metabolic profiles in dairy herd problem investigation. *Veterinary Clinics of North America: Food Animal Practice* , 25(1), 195-210.

Dunn, W. B., Bailey, N. J., & Johnson, H. E. (2005). Measuring the metabolome: current analytical technologies. *The Analyst*, 130(5), 606-625.

Emwas, A. H., Luchinat, C., Turano, P., Tenori, L., Salek, R. M., Ryan, D., & Wehrens, R. (2015). Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. *Metabolomics* , 11(4), 872-894.

Ferlizza, E., Meineri, G., Pignataro, G., & Tira, M. E. (2020). Metabolomic profile of hypothyroid dogs: a pilot study. *Veterinary Sciences*, 7(4), 183.

Forster, G. M., Heuberger, A. L., Mozzachio, K., Broeckling, C. D., & Ryan, E. P. (2018). Metabolomic profiling of canine plasma reveals differences between healthy and obese dogs. *Metabolites* , 8(2), 26.

German, A. J., Hall, E. J., & Day, M. J. (2003). Immune-mediated disease in the dog and cat. *In Practice*, 25(1), 8-21.

Goek, O. N., Prehn, C., Sekula, P., Römisch-Margl, W., Döring, A., Gieger, C.,... & Köttgen, A. (2015). Metabolites associate with kidney function and incident chronic kidney disease. *Journal of the American Society of Nephrology* , 26(9), 2332-2342.

Griffin, J. L. (2003). Metabonomics: 'fingerprinting' genes and organisms. *Nature Reviews Molecular Cell Biology*, 4(12), 946-957.

Griffin, J. L., & Shockcor, J. P. (2004). Metabolic profiles of cancer cells. *Nature Reviews Cancer*, 4(7), 551-561.

Haas, J., Frese, K. S., Park, Y. J., Katus, H. A., & Meder, B. (2021). Alterations in the plasma metabolome of patients with dilated cardiomyopathy. *ESC Heart Failure*, 8(3), 2275-2284.

Hall, E. J. (2009). Inflammatory bowel disease in the dog and cat. *Journal of Small Animal Practice*, 50(S1), 2-3.

Hallan, S. I., Sharma, K., & Zivna, M. (2017). New markers for chronic kidney disease. *Current Opinion in Nephrology and Hypertension* , 26(1), 43-50.

Hendrickson, B. A., Gokhale, R., & Cho, J. H. (2002). Clinical aspects and pathophysiology of inflammatory bowel disease. *Clinical Microbiology Reviews*, 15(1), 79-94.

Hu, T., Liu, Y., Zhang, Y., & Chen, X. (2019). Combination of mass spectrometry analysis and bioinformatic analysis for characterizing anti-inflammation active components from Boschniakia rossica and the targets. *Journal of Chromatography A* , 1603, 319-328.

Imbery, J., Salavati, S., Salin, S., Anturaniemi, J., Hielm-Björkman, A., & Sampo, M. (2022a). Plasma NMR metabolomics reveals a powerful multi-marker signature in canine inflammatory conditions. *bioRxiv*.

Imbery, J., Salavati, S., Salin, S., Anturaniemi, J., Hielm-Björkman, A., & Sampo, M. (2022b). Metabolomics studies in canine endocrine abnormalities are sparse and basic information on these abnormalities must be generated. *Research Square*.

Jendrny, P., Schulz, C., Twele, F., Meller, S., von Köckritz-Blickwede, M., Osterhaus, A. D.,... & Volk, H. A. (2020). Scent dog identification of samples from COVID-19 patients. *BMC Infectious Diseases*, 20(1), 1-7.

Jeong, S. Y., Lee, J. H., Kim, H. W., & Park, H. M. (2022). Olfactory detection of prostate and bladder cancer cells by trained sniffer dogs. *Journal of Veterinary Medical Science* , 84(1), 108-114.

Jones, D. P., & Cheung, Y. (2007). Metabolomics and its role in human health. *Journal of Nutrition* , 137(1), 251S-256S.

Jones, G. L., Tay, W. J., & Cooper, C. (2014). Metabolomics in veterinary science. *Veterinary Journal*, 201(2), 125-131.

Khor, B., Gardet, A., & Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. *Nature*, 474(7351), 307-317.

Kirwan, J. A. (2013). Metabolomics in veterinary science. *Veterinary Journal*, 195(1), 10-11.

Kol, A., Arzi, B., Athanasiou, K. A., Farmer, D. L., Nolta, J. A., Rebhun, R. B.,... & Borjesson, D. L. (2016). Companion animals: a translational model for mesenchymal stem cell therapy. *Stem Cells Translational Medicine*, 5(8), 1040-1051.

Lamers, R. J., van Nesselrooij, J. H., Spies-Faber, E. J., De Groot, M. J., van der Heijden, R., & Verpoorte, R. (2003). A strategy for quality control of herbal medicines using a combination of metabolomics and classical analysis: the example of Scutellaria. *Planta Medica*, 69(10), 957-963.

Li, Q., Freeman, L. M., Rush, J. E., Huggins, G. S., Kennedy, A. D., Labuda, J. A.,... & Laflamme, D. P. (2015). Metabolomics and transcriptomics identify pathways associated with canine myxomatous mitral valve disease. *Journal of Veterinary Internal Medicine*, 29(4), 1034-1043.

Li, Q., He, B., & Li, J. (2000). Matrix metalloproteinases and their tissue inhibitors in cardiac remodeling. *Heart Failure Reviews*, 5(3), 271-283.

Li, Q., Laflamme, D. P., & Bauer, J. E. (2021). Metabolomics analysis reveals deranged energy metabolism and amino acid metabolic reprogramming in dogs with myxomatous mitral valve disease. *Journal of the American Heart Association*, 10(10), e018923.

Lu, W., Su, X., Klein, M. S., Lewis, I. A., Fiehn, O., & Rabinowitz, J. D. (2012). Metabolite measurement: pitfalls and protocols. *Metabolomics*, 8(1), 17-35.

Majumder, A., Misra, B. B., & Choi, H. K. (2021). Recent advances in mass spectrometry-based metabolomics. *Analytical and Bioanalytical Chemistry*, 413(25), 6249-6261.

Martin, R. C., Mok, M. C., & Mok, D. W. (1999). A gene encoding the cytokinin enzyme zeatin O-xylosyltransferase of Phaseolus vulgaris. *Plant Physiology*, 120(2), 553-558.

Metwaly, A., Aldhahrani, A., Al-Saeed, S., Al-Ghamdi, S., & El-Kafrawy, S. A. (2020). Untargeted metabolomics reveals potential biomarkers for early detection of colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, 146(12), 3133-3142.

Mokkala, K., Pellonperä, O., Houttu, N., Rönnemaa, T., Laitinen, K., & Isolauri, E. (2020). Metabolomics reveals distinct profiles of mothers with gestational diabetes and their offspring. *The Journal of Clinical Endocrinology & Metabolism*, 105(10), e3637-e3649.

Montague, Z. A., Park, H. R., & Se-Kwon, K. (2022). Metabolomics in sepsis: a decade in review. *Metabolites*, 12(11), 1084.

Muñoz-Prieto, A., López-García, M. A., & Mayor-Lorenzo, A. (2021). Metabolomics in canine chronic kidney disease: a review. *Veterinary Sciences*, 8(10), 226.

Murarka, S., Moukalled, D., & Mian, M. A. (2019). Training dogs to detect cancer by smelling volatile organic compounds. *Journal of Veterinary Internal Medicine* , 33(4), 1469-1476.

Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. *Nature Reviews Drug Discovery*, 1(2), 153-161.

Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999). 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*, 29(11), 1181-1189.

Ottka, C., Szabó, A., Sterczer, A., & Manczur, F. (2021a). Serum glycoprotein acetyls (GlycA) concentrations in dogs with hypo - and hyperadrenocorticism. *Acta Veterinaria Hungarica* , 69(2), 123-128.

Ottka, C., Szabó, A., Sterczer, A., & Manczur, F. (2021b). Serum glycoprotein acetyls (GlycA) concentrations in dogs with elevated liver enzyme activities and hyperlipidemia. *Acta Veterinaria Hungarica* , 69(3), 245-250.

Pacheco-Navarro, M., & Rogers, M. (2023). Metabolomic and lipidomic analysis of sepsis. *Metabolites* , 13(2), 228.

Payne, J. M., Dew, S. M., Manston, R., & Faulks, M. (1970). The Compton metabolic profile test. *Veterinary Record*, 87(6), 150-158.

Rajabi, M., Kassiotis, C., Razeghi, P., & Taegtmeyer, H. (2007). Return to the fetal gene program protects the stressed heart: a strong hypothesis. *Heart Failure Reviews*, 12(3-4), 331-343.

Schrimpe-Rutledge, A. C., Codreanu, S. G., Sherrod, S. D., & McLean, J. A. (2016). Untargeted metabolomics strategies —challenges and emerging directions. *Journal of the American Society for Mass Spectrometry* , 27(12), 1897-1905.

Seo, K. W., Lee, J. H., & Park, H. M. (2018). Olfactory detection of breast and colorectal cancer cells by trained sniffer dogs. *Journal of Veterinary Medical Science* , 80(1), 124-129.

Sesh, S., Kumar, A., & Kumar, R. (2017). Evaluation of serum cardiac troponin I, creatine kinase-MB and lactate dehydrogenase in canine dilated cardiomyopathy. *Indian Journal of Animal Research*, 51(3), 565-568.

Shah, S. H., Sun, J. L., Stevens, R. D., Bain, J. R., Muehlbauer, M. J., & Kraus, W. E. (2012). Metabolomic profiling for the identification of novel biomarkers and mechanisms related to adverse cardiovascular events in stable coronary artery disease. *Circulation* , 126(9), 1110-1120.

Slovak, J. E., & Wang, C. (2014). The utility of the canine inflammatory bowel disease activity index (CIBDAI) in assessing clinical response to treatment in dogs with idiopathic inflammatory bowel disease. *Journal of the American Animal Hospital Association*, 50(5), 323-328.

Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005). Myocardial substrate metabolism in the normal and failing heart. *Physiological Reviews*, 85(3), 1093-1129.

Suchodolski, J. S., Markel, M. E., Garcia-Mazcorro, J. F., Unterer, S., Heilmann, R. M., & Dowd, S. E. (2012). The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. *PLoS One*, 7(12), e51907.

Tomita, M., & Nishioka, T. (2005). *Metabolomics: the frontier of systems biology*. Springer.

Tounta, V., Liu, Y., Che, N., & Ligresti, G. (2021). Application of metabolomics in infectious diseases. *Journal of Biomedical Research*, 35(1), 1-13.

Vignoli, A., Ghini, V., Meoni, G., & Tenori, L. (2023). NMR-based metabolomics for clinical research and diagnostics. *Journal of Magnetic Resonance*, 348, 107383.

Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., & DuGar, B. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*, 472(7341), 57-63.

Want, E. J., Wilson, I. D., Gika, H., Theodoridis, G., Plumb, R. S., Shockcor, J.,... & Nicholson, J. K. (2010). Global metabolic profiling procedures for urine by ultraperformance liquid chromatography-mass spectrometry. *Nature Protocols*, 5(6), 1005-1018.

Weckwerth, W., & Fiehn, O. (2002). Can we find new biomarkers for plant systems biology using metabolomics? *Trends in Biotechnology*, 20(3), S43-S47.

Wilson, I. D., Plumb, R., Granger, J., Major, H., Williams, R., & Lenz, E. M. (2005). HPLC-MS-based methods for the study of metabonomics. *Journal of Chromatography B*, 817(1), 67-76.

Yang, J., Xu, G., Zheng, Y., Kong, H., Pang, T., & Wang, Y. (2004). Strategy for metabonomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry. *Journal of Chromatography A*, 1058(1-2), 117-124.

Zhao, Q., Liu, J., Zhu, W., Sun, C., & Ge, J. (2020). Plasma metabolomics profiling of dilated cardiomyopathy. *Journal of Cellular and Molecular Medicine*, 24(1), 745-754.

Works cited

1. Metabolomics in the study of spontaneous animal diseases - PMC, accessed

September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7488963/
2. Canine metabolomics advances - ProQuest, accessed September 19, 2025, https://search.proquest.com/openview/b636c9e49974a94ac0b07d7f4c14a380/1?pq-origsite=gscholar&cbl=326279
3. Comparative plasma and urine metabolomics analysis of juvenile and adult canines, accessed September 19, 2025, https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.1037327/full
4. An introduction to metabolomics and its potential application in veterinary science | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/5872490_An_introduction_to_metabolomics_and_its_potential_application_in_veterinary_science
5. Canine metabolomics advances | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/338679016_Canine_metabolomics_advances
6. Metabolomics and livestock genomics: Insights into a phenotyping ..., accessed September 19, 2025, https://academic.oup.com/af/article/6/1/73/4638799
7. Livestock metabolomics and the livestock metabolome: A systematic review - Semantic Scholar, accessed September 19, 2025, https://pdfs.semanticscholar.org/002d/420f3afaa65c60d4c8bf9d1d6e7234b1c88c.pdf
8. Correlation of urinary biomarkers with chronic renal disease in dogs - TEXAS A&M UNIVERSITY - : NIFA Reporting Portal, accessed September 19, 2025, https://portal.nifa.usda.gov/web/crisprojectpages/0218161-correlation-of-urinary-biomarkers-with-chronic-renal-disease-in-dogs.html
9. Biomarkers for chronic kidney disease in dogs: a comparison study - PMC - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7468053/
10. Canine Traditional Laboratory Tests and Cardiac Biomarkers - Frontiers, accessed September 19, 2025, https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2020.00320/full
11. Metabolomics as a diagnostic tool for hepatology: validation in a naturally occurring canine model - University of Liverpool, accessed September 19, 2025, https://www.liverpool.ac.uk/pfg/PDF/05_Whitfield_Metab.pdf
12. Metabolomics in canine hepatology | Centre for Proteome Research, accessed September 19, 2025, https://www.liverpool.ac.uk/pfg/Research/Pubs/files/59ef701b5e773af3aba1757940055438-46.html
13. Metabolic Profiles for Evaluation of the Transition Period - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/265996128_Metabolic_Profiles_for_Evaluation_of_the_Transition_Period

14. Content 1. Introduction 2. Literature review 2.1. Metabolic profile test 2.2. Most important metabolic disorders 2.3. Most impor, accessed September 19, 2025, https://huveta.hu/bitstream/handle/10832/811/KerteszOmerThesis.pdf?sequence=1&isAllowed=y
15. Metabolic profile testing - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/3061615/
16. Veterinary & Animal Health - Metabolon, accessed September 19, 2025, https://www.metabolon.com/applications/veterinary-animal-health/
17. Profiling of Serum Metabolites in Canine Lymphoma Using Gas ..., accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4272985/
18. Metabolomics and Transcriptomics of the Common Degenerative Mitral Valve Disease in Dogs- Purina Vet Centre, accessed September 19, 2025, https://vetcentre.purina.co.uk/sites/default/files/2025-06/01_Li_2015_Metabolomics_and_transcriptomics_MMVD_Study%202.pdf
19. Meat Animal Biologics Discovery Opportunities from the Gut Microbiome: Application of Metabolomics - Iowa State University Digital Press, accessed September 19, 2025, https://www.iastatedigitalpress.com/mmb/article/id/18261/
20. Combined Untargeted and Targeted Metabolomics Approaches Reveal Urinary Changes of Amino Acids and Energy Metabolism in Canine Babesiosis With Different Levels of Kidney Function - Frontiers, accessed September 19, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.715701/full
21. Healthy and Chronic Kidney Disease (CKD) Dogs Have Differences ..., accessed September 19, 2025, https://www.mdpi.com/2218-1989/11/11/782
22. Alteration of the fecal microbiota and serum metabolite profiles in ..., accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4615558/
23. Metabolomics for the Identification of Biomarkers in Kidney Diseases - Nanotheranostics, accessed September 19, 2025, https://www.ntno.org/v09p0110.htm
24. Healthy and Chronic Kidney Disease (CKD) Dogs Have Differences in Serum Metabolomics and Renal Diet May Have Slowed Disease Progression, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8623449/
25. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8200728/
26. Canine Mitral Valve Disease Case Study- Metabolon, accessed September 19, 2025, https://www.metabolon.com/resources/case-studies/canine-heart-disease/
27. Metabolome Profiling in the Plasma of Dogs with Idiopathic Dilated ..., accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10607069/
28. Characteristics of healthy dogs and dogs with lymphoma | Download Table - ResearchGate, accessed September 19, 2025,

https://www.researchgate.net/figure/Characteristics -of-healthy-dogs-and-dogs-with-lymphoma_tbl1_264868352
29. Profiling of Serum Metabolites in Canine Lymphoma Using Gas Chromatography Mass Spectrometry - J-Stage, accessed September 19, 2025, https://www.jstage.jst.go.jp/article/jvms/76/11/76_14-0043/_article
30. Metabolomic and Clinical Disturbances in Canine Inflammatory Bowel Disease | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/352624021_Metabolomic_and_Clinical_Disturbances_in_Canine_Inflammatory_Bowel_Disease
31. NMR-based-Metabolomics Evaluation in Dogs Infected with Canine Parvovirus: A New Approach for Biomarker/s | Veterinaria Italiana, accessed September 19, 2025, https://www.veterinariaitaliana.izs.it/index.php/VetIt/article/view/3578
32. (PDF) Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/345739464_Untargeted_metabolomic_analysis_in_naturally_occurring_canine_diabetes_mellitus_identifies_similarities_to_human_Type_1_Diabetes
33. Plasma metabolomics profile in patients with Cushing's syndrome - Endocrine Abstracts, accessed September 19, 2025, https://www.endocrine-abstracts.org/ea/0041/ea0041gp29
34. Metabolomic analyses of serum samples from dogs in the groups of... - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/figure/Metabolomic-analyses-of-serum-samples-from-dogs-in-the-groups-of-hyperadrenocorticism_fig1_359858532
35. Renal Biomarkers in Companion Animals—A Review - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11939308/
36. Early Detection of Chronic Kidney Disease Using Plasma Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 in Small-Breed Dogs: A Retrospective Pilot Study - MDPI, accessed September 19, 2025, https://www.mdpi.com/2076-2615/14/16/2313
37. canine cardiac biomarkers: nature, activity and use - Exploratory Animal and Medical Research, accessed September 19, 2025, https://animalmedicalresearch.org/Vol.14_Issue-1_June_2024/Canine%20cardiac%20biomarkers-%20nature,%20activity%20and%20use.pdf
38. Canine Immunosuppressant-Responsive Enteropathy (Inflammatory Bowel Disease), accessed September 19, 2025, https://www.purinainstitute.com/centresquare/therapeutic-nutrition/canine-immunosuppressant-responsive-enteropathy
39. Cushing Disease (Pituitary-Dependent Hyperadrenocorticism) in Animals - Endocrine System - Merck Veterinary Manual, accessed September 19, 2025, https://www.merckvetmanual.com/endocrine-system/the-pituitary-

gland/cushing-disease-pituitary-dependent-hyperadrenocorticism-in-animals
40. Cushing's syndrome | Cornell University College of Veterinary Medicine, accessed September 19, 2025, https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/cushings-syndrome
41. Salivary metabolomic identification of biomarker candidates for oral melanoma and oral squamous cell carcinoma in dogs - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11256132/
42. NMR-based metabolomics study of canine bladder cancer - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/22967815/
43. (PDF) Canine-Inspired Chemometric Analysis of Volatile Organic Compounds in Urine Headspace to Distinguish Prostate Cancer in Mice and Men - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/368700648_Canine-Inspired_Chemometric_Analysis_of_Volatile_Organic_Compounds_in_Urine_Headspace_to_Distinguish_Prostate_Cancer_in_Mice_and_Men
44. Fecal microbiota composition, serum metabolomics, and markers of inflammation in dogs fed a raw meat-based diet compared to those on a kibble diet - Frontiers, accessed September 19, 2025, https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1328513/full

(*) This document was researched using the following AI tools: Google 2.5 Pro Deep Research, Anthropic Opus 4.1 and OpenAI 5.0 Research;